Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

9.7%

7 terminated/withdrawn out of 72 trials

Success Rate

80.6%

-6.0% vs industry average

Late-Stage Pipeline

13%

9 trials in Phase 3/4

Results Transparency

10%

3 of 29 completed trials have results

Key Signals

17 recruiting3 with results7 terminated

Enrollment Performance

Analytics

Phase 2

46(74.2%)

Phase 3

7(11.3%)

Phase 1

5(8.1%)

Phase 4

2(3.2%)

N/A

2(3.2%)

62Total

Phase 2(46)

Phase 3(7)

Phase 1(5)

Phase 4(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (72)

Showing 20 of 72 trials

NCT07260175Phase 2Recruiting

Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

Role: lead

NCT07542678Phase 2Not Yet Recruiting

Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept

Role: lead

NCT06731803Phase 1Active Not Recruiting

Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma

Role: lead

NCT07387198Phase 2Not Yet Recruiting

Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab

Role: lead

NCT07110038Phase 2Recruiting

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Role: lead

NCT03081143Phase 2Active Not Recruiting

Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

Role: lead

NCT05798156Phase 2Active Not Recruiting

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Role: lead

NCT05393674Phase 2Completed

Fedratinib in Combination With Nivolumab

Role: lead

NCT07507968Phase 2Not Yet Recruiting

TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma

Role: lead

NCT04351256Phase 2Completed

Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy

Role: lead

NCT06178445Phase 2Active Not Recruiting

Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer

Role: lead

NCT03753659Phase 2Completed

IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)

Role: lead

NCT06981325Phase 2Recruiting

Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

Role: lead

NCT05689671Phase 4Active Not Recruiting

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

Role: collaborator

NCT04318938Phase 2Active Not Recruiting

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Role: lead

NCT03252938Phase 1Active Not Recruiting

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Role: lead

NCT04522544Phase 2Recruiting

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Role: lead

NCT05460000Phase 2Recruiting

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

Role: collaborator

NCT04122872Recruiting

GISAR German Interdisciplinary Sarcoma Registry

Role: lead

NCT07365930Recruiting

NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy

Role: lead